5 Questions on Melanoma

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Experts weigh in on the practical applications of PSMA PET imaging

$Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Tim Cortese

Exploring Burnout Causes and Management in Oncologic Practice

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Eric P. Winer, MD

June 2nd 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Gina Mauro

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Ashling Wahner

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

Related Content

Roman Fabbricatore

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Experts weigh in on the practical applications of PSMA PET imaging

$Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Tim Cortese

Exploring Burnout Causes and Management in Oncologic Practice

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Eric P. Winer, MD

June 2nd 2025

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Gina Mauro

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Ashling Wahner